Considering coding mutations of TP53 occur relatively early in the development of lung cancer, usually before the tumor metastasizes (46), we speculated this is one of the reasons that TP53 show a superior prognostic value in low-risk patients. The gene discussed is TP53; the disease is lung cancer.